Collegium Pharmaceutical (COLL) Revenue (2016 - 2026)

Collegium Pharmaceutical's Revenue history runs 11 years deep, the most recent figure standing at $193.5 million for Q1 2026.

• In Q1 2026, Revenue rose 8.87% year-over-year to $193.5 million; the TTM figure through Mar 2026 stood at $796.3 million (up 55.25% YoY), while the FY2025 annual figure was $780.6 million, up 23.62% from the prior year.
• Revenue was $193.5 million for Q1 2026 at Collegium Pharmaceutical, down from $205.4 million in the prior quarter.
• In the past five years, Revenue ranged from a high of $209.4 million in Q3 2025 to a low of $3.6 million in Q1 2022.
• Historically, Revenue has averaged $141.5 million across 5 years, with a median of $144.9 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Revenue slumped 95.86% in 2022, then surged 3882.59% in 2023.
• A 5-year view of Revenue shows it stood at $129.6 million in 2022, then grew by 15.53% to $149.7 million in 2023, then advanced by 21.51% to $181.9 million in 2024, then rose by 12.92% to $205.4 million in 2025, then dropped by 5.81% to $193.5 million in 2026.
• The last three Revenue figures came in at $193.5 million (Q1 2026), $205.4 million (Q4 2025), and $209.4 million (Q3 2025), per Business Quant data.